⁃ Patients must meet the following criteria for study entry::

• Signed Informed Consent Form

• Age ≥ 18 years at enrollment

• At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy

• Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma.

• Conditional treatment with obinutuzumab in combination with lenalidomide